Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 2 2Phase 1/2 2Phase 1 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Carcinoma, Non-Small-Cell Lung 438Neoplasms 363Breast Neoplasms 260Colorectal Neoplasms 243Neoplasm Metastasis 213Melanoma 209Leukemia, Myeloid, Acute 188Multiple Myeloma 187Pancreatic Neoplasms 181Ovarian Neoplasms 178Recurrence 173Prostatic Neoplasms 161Lymphoma, Non-Hodgkin 142Stomach Neoplasms 133Squamous Cell Carcinoma of Head and Neck 127Lung Neoplasms 125Lymphoma 121Carcinoma, Hepatocellular 117Carcinoma, Renal Cell 102Triple Negative Breast Neoplasms 100Leukemia, Lymphocytic, Chronic, B-Cell 99Glioblastoma 97Leukemia 93Advanced Solid Tumor 92Small Cell Lung Carcinoma 91Lymphoma, Large B-Cell, Diffuse 90Head and Neck Neoplasms 87Advanced Solid Tumors 84Endometrial Neoplasms 79Myelodysplastic Syndromes 78

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × Pathologic Complete Response × Clear all
NCT02789254 2023-12-28

FLYSYN-101

Synimmune GmbH

Phase 1/2 Completed
31 enrolled
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Leukemia, Myeloid, Acute

NCT01520558 2017-06-29

CNDO-109-AANK for AML in First Complete Remission (CR1)

Coronado Biosciences, Inc.

Phase 1/2 Unknown
12 enrolled 11 charts
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡